B of A Securities Maintains Buy on Amicus Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Tazeen Ahmad maintains a Buy rating on Amicus Therapeutics (NASDAQ:FOLD) but lowers the price target from $14 to $13.

May 10, 2024 | 11:42 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Despite the reduction in price target from $14 to $13 by B of A Securities, the firm maintains a Buy rating on Amicus Therapeutics.
The reduction in price target could have a mixed impact. On one hand, it suggests a lower expected future price, potentially negative. On the other hand, maintaining a Buy rating indicates a positive outlook on the company's fundamentals and potential growth, which could mitigate negative sentiment. The net impact is likely neutral in the short term as investors weigh the lowered price target against the continued positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100